Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2024.115071 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Hedwig M Blommestein und 17 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus School of Health Policy and Management, Erasmus University Rotterdam, the Netherlands. Electronic address: blommestein@ehspm.eur.nl. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Melanoma, Mutation, Skin Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Erasmus School of Health Policy and Management, Erasmus University Rotterdam, the Netherlands. Electronic address: blommestein@ehspm.eur.nl.
- Erasmus School of Health Policy and Management, Erasmus University Rotterdam, the Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands.
- Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands; Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands; Department of Biomedi…
- Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands.
- Department of Medical Oncology, Zuyderland Medical Center Sittard, Sittard-Geleen, the Netherlands.
Zitieren
APA
Blommestein, H. M., de Groot, S., Leeneman, B., Uyl-de Groot, C. A., Haanen, J. B. A. G., Wouters, M. W. J. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blokx, W. A. M., Boers-Sonderen, M. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., van Not, O. J., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., & Franken, M. G. (2025). Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115071
Vancouver
Blommestein HM, de Groot S, Leeneman B, Uyl-de Groot CA, Haanen JBAG, Wouters MWJM, et al. Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2024.115071
BibTeX
@article{Blommestein2025,
author = {Blommestein, Hedwig M and de Groot, Saskia and Leeneman, Brenda and Uyl-de Groot, Carin A and Haanen, John B A G and Wouters, Michel W J M and Aarts, Maureen J B and van den Berkmortel, Franchette W P J and Blokx, Willeke A M and Boers-Sonderen, Marye J and van den Eertwegh, Alfons J M and de Groot, Jan Willem B and Hospers, Geke A P and Kapiteijn, Ellen and van Not, Olivier J and van der Veldt, Astrid A M and Suijkerbuijk, Karijn P M and Franken, Margreet G},
title = {Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2024.115071}
}
EUVIMED